October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
63 citations
,
January 2001 in “AIDS” The document reported a case of a 30-year-old HIV-infected man who developed alopecia universalis and Graves' disease following immune restoration after starting highly active antiretroviral therapy (HAART). Initially, the patient showed a significant increase in CD4 cell count and suppression of viral load after HAART initiation. However, he experienced total body hair loss and was diagnosed with alopecia universalis, followed by the onset of Graves' disease. The case highlighted that immune reconstitution in AIDS patients on HAART could lead to autoimmune manifestations, possibly due to unbalanced regrowth of autoreactive and immunoregulatory components during intense immune repopulation. This case was notable as alopecia universalis had not been previously reported in HIV patients post-HAART initiation or in association with thyroid disease.
15 citations
,
July 2004 in “AIDS” Indinavir therapy can cause reversible skin, hair, and nail darkening.
14 citations
,
August 2010 in “Journal of Investigative Dermatology” HPV does not cause aggressive cancer in RDEB patients.
52 citations
,
January 2022 in “Current Research in Pharmacology and Drug Discovery” New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.